Navigation Links
Veracyte, Inc. Files Registration Statement for Initial Public Offering
Date:9/20/2013

overing, developing and commercializing molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment, thus helping patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma® Thyroid FNA Analysis, includes the Gene Expression Classifier (GEC). The GEC helps physicians reduce the number of unnecessary surgeries by employing a proprietary 142-gene signature to preoperatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The clinical utility and cost effectiveness of the GEC have been demonstrated in studies published in peer-reviewed journals and the clinical validity of the GEC has been demonstrated in a study published in The New England Journal of Medicine in 2012. Since the commercial launch of Afirma in January 2011, Veracyte has processed over 50,000 fine needle aspiration (FNA) samples for evaluation using Afirma and has performed more than 10,000 GECs to resolve indeterminate cytopathology results. Veracyte has obtained positive coverage decisions for Afirma from Aetna, Humana, Medicare and UnitedHealthcare. Collectively, these payers represent more than 100 million covered lives. Afirma is marketed and sold in the United States through a global co-promotion agreement with Genzyme Corporation, a subsidiary of Sanofi.

Veracyte and Afirma are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.


'/>"/>
SOURCE Veracyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
2. Adheris Inc. Files For Preliminary Injunction To Stop U.S. Government From Infringing On Constitutionally Protected Speech
3. Perrigo Files Registration Statement On Form S-4 In Connection With Proposed Acquisition Of Elan
4. Cell Therapy - Technologies, Markets and Companies - Updated 2013 with New Companies and Profiles
5. Steven Zecola Files a Citizens Petition with the FDA for a New Approach to Address Metastatic Cancer
6. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
7. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against Dr. Yamanaka for Deception
8. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
9. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012
10. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... PORTLAND, Oregon , August 4, 2015 /PRNewswire/ ... published by Allied Market Research, titled, "World Cardiac ... global cardiac biomarker market would generate the revenue ... of 18.9% from 2015 to 2020. Cardiac Troponins ... throughout the forecast period due to high sensitivity ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... diagnostic tests – today announced that Robert A. Gregg, PhD, has joined RPS ... than 30 years of relevant experience and remarkable achievements in the medical device ...
(Date:8/4/2015)... Aug. 4, 2015  Blueprint Medicines (NASDAQ: BPMC ... kinase drugs for genomically defined diseases, today announced that ... a company overview at the 2015 Wedbush PacGrow Healthcare ... EDT. A live webcast of the event ... the Blueprint Medicines website at www.blueprintmedicines.com . An ...
(Date:8/4/2015)... Francisco, CA (PRWEB) , ... August 04, 2015 , ... ... difference by inviting a diverse selection of entrepreneurs from across the United States to ... CEO Jessica Richman is honored to be chosen to be among the attendees. , ...
Breaking Biology Technology:Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2
... Electronic health record systems generally are perceived to have ... more clinics consider moving from paper charts to EHR ... barriers to entry. , ,The evolution of systems for ... robust data security has prompted more hospitals and ...
... - Just six weeks after taking the helm at ... to pursue opportunities in the private sector, the organization announced. ... has served as general counsel to WiCell's parent, the ... high-tech and biotechnology industries. , ,Donley, who joined WARF in ...
... An education research team at the University of Wisconsin-Madison ... to study the impact of digital media on youth ... investment will support 24 national studies of different aspects of ... , ,"What MacArthur is actually trying to do, with this ...
Cached Biology Technology:GE Healthcare launches hybrid electronic record 2Donley resigns as WiCell director 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... a form of breast cancer known as estrogen receptor positive ... the treatment and prevention of recurring breast cancer. Currently, ... dose is prescribed for every patient. New research at ... patient-specific genetic factors, lack of exposure to vitamin D during ...
... DNA code for a complex region of the human genome ... Fraser University, chart new territory in immunity research. , They ... how well they operate and, potentially, what they fight off, ... drugs, treatments and vaccinations are designed to treat whole populations ...
... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... study of seven missense variants of the BRCA1 gene ... to the risk of suffering breast or ovarian cancer. ... PLoS One The classification of these three ...
Cached Biology News:Cold winters freezing out breast cancer treatment 2Scientists find ethnicity linked to antibodies 2Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene 2
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Biology Products: